文献速递核素与放射性配体治疗肿瘤 PET/CT

[212Pb]Pb-DOTAMTATE与其他SSTR2靶向化合物的体内性能直接比较

Side-by-Side Comparison of the In Vivo Performance of [212Pb]Pb-DOTAMTATE and Other SSTR2-Targeting Compounds.
PubMed 文献 · J Nucl Med · 2025-03-03

该临床前研究在AR42J肿瘤动物模型中,将DOTAMTATE、DOTATATE、JR11及PSC-PEG2-TOC等SSTR2类似物与拮抗剂分别用DOTAM、PSC或DOTA螯合剂制备并经212Pb标记后直接比较。结果显示DOTAM螯合效率更高、动力学更快,其次为DOTA,均优于PSC;[212Pb]Pb-DOTAMTATE的肿瘤-肾脏曲线下面积比优于其他212Pb标记的SSTR2靶向肽。作者认为其肿瘤滞留良好、剂量学特征更有利。

要点

  • DOTAM螯合效率高、动力学快,优于DOTA,DOTA优于PSC。
  • [212Pb]Pb-DOTAMTATE肿瘤-肾脏曲线下面积比优于其他212Pb标记SSTR2靶向肽。
  • 作者认为该药肿瘤滞留良好、剂量学更有利,适用于SSTR2阳性神经内分泌肿瘤的靶向α治疗。

核心结论

  • 结果表明[212Pb]Pb-DOTAMTATE肿瘤滞留良好、剂量学特征更有利,这对SSTR2阳性神经内分泌肿瘤的靶向α治疗至关重要。

研究设计与样本

  • 临床前研究:将SSTR2类似物分别用DOTAM、PSC或DOTA螯合剂制备,经212Pb标记后在AR42J肿瘤荷瘤动物中直接比较螯合、定量与药代动力学。

主要发现

  • DOTAM螯合效率更高且动力学更快,其次为DOTA,均优于PSC。
  • [212Pb]Pb-DOTAMTATE的肿瘤-肾脏曲线下面积比优于其他经212Pb标记的SSTR2靶向肽。

关键数值与推荐

  • DOTAM与DOTA的螯合效率和动力学均优于PSC;[212Pb]Pb-DOTAMTATE的肿瘤-肾脏曲线下面积比优于其他212Pb标记的SSTR2靶向肽。

临床怎么用

  • 作者认为[212Pb]Pb-DOTAMTATE肿瘤滞留良好、剂量学更有利,对SSTR2阳性神经内分泌肿瘤的靶向α治疗至关重要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There are numerous versions of octreotide and octreotate, including DOTAMTATE, DOTATATE, JR11, and lead-specific chelator (PSC)-PEG2-TOC. These peptides, which can be either analogs or antagonists, are used in nuclear medicine for diagnostic imaging or targeted radionuclide therapy of neuroendocrine tumors that are positive for somatostatin receptors (SSTRs). Despite their structural and targeting similarities, they have distinct properties and clinical uses. We aimed to perform an extensive preclinical comparison of all these somatostatin analogs with 212Pb, directly studying their pharmacokinetic properties in tumors overexpressing SSTR2. Methods: All SSTR2 analogs were manufactured with the DOTAM, PSC, or DOTA chelators for appropriate comparison after radiolabeling with 212Pb. Chelation, quantification, and pharmacokinetics were compared side by side in AR42J-tumor-bearing animals. Results: These findings highlight the superior chelation efficiency and faster kinetics of DOTAM and then DOTA compared with the PSC. We also discovered a superior tumor-to-kidney area under the curve ratio for [212Pb]Pb-DOTAMTATE over other SSTR2-targeting peptides when radiolabeled with 212Pb. Conclusion: Taken together, the results indicates that [212Pb]Pb-DOTAMTATE has favorable tumor retention and a more favorable dosimetry profile, which is crucial for targeted α-therapy in treating SSTR2-positive neuroendocrine tumors.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Saidi A, Stallons TA, Wong AG, et al. Side-by-Side Comparison of the In Vivo Performance of [212Pb]Pb-DOTAMTATE and Other SSTR2-Targeting Compounds. J Nucl Med. 2025. PMID: 39884771. doi:10.2967/jnumed.124.268345

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。